Toshifumi Yamaguchi

Dr. Toshifumi Yamaguchi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
TYToshifumi Yamaguchi
Toshifumi Yamaguchi
SISatoru Iwasa
Satoru Iwasa
HSHirokazu Shoji
Hirokazu Shoji
YHYoshitaka Honma
Yoshitaka Honma
ATAtsuo Takashima
Atsuo Takashima
NBNarikazu Boku
Narikazu Boku

8 March 2018 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TYToshifumi Yamaguchi
Toshifumi Yamaguchi
KKKen Kato
Ken Kato
KNKengo Nagashima
Kengo Nagashima
SISatoru Iwasa
Satoru Iwasa
YHYoshitaka Honma
Yoshitaka Honma
KHKazuhide Higuchi
Kazuhide Higuchi

25 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
HTHiroya Taniguchi
Hiroya Taniguchi
KUKay Uehara
Kay Uehara
TIToshiaki Ishikawa
Toshiaki Ishikawa
OOOsamu Okochi
Osamu Okochi
NANaoya Akazawa
Naoya Akazawa
TMToshiki Masuishi
Toshiki Masuishi
Background/Objectives: BRAF mutations occur in 5–10% of metastatic colorectal cancer (mCRC) cases, but their implications for prognosis and optimal treatment remain unclear. Methods: This multicenter, prospective observational study analyzed 377 RAS wild-type cases from 511 patients across 32 centers, using PCR-based methods. Results: BRAF mutations were identified in 21% (79/377) of cases, predominantly V600E (89.9%) with a minority of non-V600E (10.1%). Microsatellite instability (MSI) testing revealed MSI-high in 11.3%, exclusively among V600E cases. V600E mutations were linked to right-sided tumors, poor differentiation, and elevated CA19-9 levels. Median survival was significantly lower in V600E cases compared to BRAF wild-type (12.4 vs. 37.5 months, HR 3.25, p < 0.001) and marginally lower non-V600E cases (12.4 vs. 34.7 months, HR 0.61, p = 0.057). Chemotherapy regimens (doublet vs. triplet) and targeted treatments (bevacizumab vs. anti-EGFR) showed no significant survival differences in V600E patients. Similarly, RAS/BRAF wild-type patients had comparable survival with bevacizumab versus anti-EGFR, even for left-sided tumors. Conclusions: These findings highlight distinct clinical and prognostic profiles for BRAF V600E and non-V600E mutations, while treatment choice appears to have limited impact on survival in these subgroups or RAS/BRAF wild-type cases.

31 March 2025 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
RTRyo Tanaka
Ryo Tanaka
SEShunji Endo
Shunji Endo
TYToshifumi Yamaguchi
Toshifumi Yamaguchi
HMHiromichi Miyagaki
Hiromichi Miyagaki
JKJunji Kawada
Junji Kawada
TSTaroh Satoh
Taroh Satoh

29 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
Atsuo TakashimaAtsuo Takashima
Atsuo Takashima
MIMegumi Ishiguro
Megumi Ishiguro
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
FNFumio Nagashima
Fumio Nagashima
C(Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG)
Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG)
Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (500 000JPY/month, and molecular targeted drugs being the main drivers of cost.

19 September 2024 in Scientific Reports
Verified
Journal Article
Open access
TYToshifumi Yamaguchi
Toshifumi Yamaguchi
KKKoshi Kumagai
Koshi Kumagai
SYShusuke Yagi
Shusuke Yagi
TNTakashi Nomura
Takashi Nomura
KNKengo Nagashima
Kengo Nagashima
NBNarikazu Boku
Narikazu Boku
This study aimed to survey the efficacy of chemotherapy regimens in the real world setting and explore the most promising regimen for patients experiencing early recurrence for gastric cancer. We retrospectively reviewed the clinical course of 207 patients with gastric cancer, who developed early recurrence during or within 6 months after completing S-1 adjuvant therapy at 19 Japanese institutions between 2012 and 2016. The treatment regimens after recurrence were fluoropyrimidines plus platinum-based regimens (FP) in 91 (44%) patients, paclitaxel-based regimens (PTX) in 102 (49%), and irinotecan-based regimens (IRI) in 14 (7%). The overall response and disease control rates were 28.7% and 54.1%. Median progression-free survival (PFS) and overall survival (OS) were 5.1 and 12.9 months, respectively. In the FP, PTX, and IRI regimens, the median PFS and OS were 5.9, 4.1, 4.1 months and 12.8, 12.9, and 11.8 months, respectively. The combination of PTX and ramucirumab showed survival comparable to capecitabine plus platinum. Multivariate analyses for OS showed that recurrence during adjuvant chemotherapy and undifferentiated histological type were independent poor prognostic factors. Although the prognosis of patients with early recurrence even with adjuvant S-1 was poor, PTX plus ramucirumab therapy could be a potential treatment option.